Paradigm Biopharmaceuticals (ASX:PAR) has activated a clinical site in Australia, with the first patient providing consent to participate in the phase three trial testing injectable pentosan polysulfate sodium (iPPS) for knee osteoarthritis pain, according to a Tuesday filing with the Australian bourse.
The trial also includes 48 US sites preparing for activation, with first patient consent and dosing expected next quarter, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.